Agilent Technologies, Inc.
NYSE:AMedical - Diagnostics & Research
+$3.04 today
- Market cap
- $50.00B
- Beta
- 1.26
- P/E (TTM)
- 25.5
- EPS (TTM)
- $5.00
- Dividend yield
- 0.59%
Volume 2.48M
Average 2.24M
A Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Agilent Technologies, Inc.NYSE: A
Total Equity · Q3 FY2026 · quarter ended Jul 2026
Total equity rises 15.6% from a year ago
Total equity stood at $7.36B at the end of Q3 FY2026, up 15.6% from a year earlier and up 3.4% from the prior quarter. Over 3 fiscal years it compounded at +8.3% a year.
Context
- Total equity amounted to 52.7% of total assets at the end of Q3 FY2026, up 0.6 pp from a year earlier.
- Total equity increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +15.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 6.74B USD
- Year-over-year change
- +14.3%
- 4-year CAGR
- +5.8%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-10-31 | 6.74B | +14.3% |
| FY2024 | 2024-10-31 | 5.9B | +0.9% |
| FY2023 | 2023-10-31 | 5.85B | +10.2% |
| FY2022 | 2022-10-31 | 5.31B | -1.6% |
| FY2021 | 2021-10-31 | 5.39B | — |
Total Equity vs competitors
How A compares with its peers on the latest reported figures
- A's Jul 2026 total equity of $7.36B is the 4th highest of the 9 companies compared; the peer median is $7.2B.
- Its year-over-year change of +15.6% is the 4th highest of 9, against a peer median of +6.2%.
- Total equity amounts to 52.7% of total assets for A, versus a peer median of 57.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $54.9B | +7.3% | +6.6% | 48.1% | |
| Sep 2026 | $53.63B | +5.0% | +1.6% | 57.5% | |
| Jul 2026 | $15.2B | +603.5% | +71.9% | 61.4% | |
| Jul 2026 | $7.36B | +15.6% | +8.3% | 52.7% | |
| Jul 2026 | $7.23B | -4.3% | -0.6% | 60.0% | |
| Jun 2026 | $7.17B | +0.6% | -8.1% | 70.0% | |
| Jun 2026 | $3.36B | -4.2% | +2.9% | 57.0% | |
| Jun 2026 | $2.42B | +29.6% | +30.4% | 40.0% | |
| Jun 2026 | $12.82M | +105.0% | — | 0.3% | |
| Peer median (excluding A) | $7.2B | +6.2% | +2.9% | 57.3% | |
Competitors are the stored peer set for A. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1.48B | 1.05B | 1.59B | 1.33B | 1.79B |
| Short-term Investments | 91M | 0 | 0 | 0 | 0 |
| Net Receivables | 1.17B | 1.41B | 1.29B | 1.32B | 1.49B |
| Inventory | 830M | 1.04B | 1.03B | 991M | 1.03B |
| Other Current Assets | 222M | 282M | 274M | 315M | 293M |
| Total Current Assets | 3.8B | 3.78B | 4.19B | 3.96B | 4.59B |
| Property, Plant & Equipment (Net) | 945M | 1.1B | 1.42B | 1.96B | 2.02B |
| Goodwill | 3.98B | 3.95B | 3.96B | 4.47B | 4.47B |
| Intangible Assets | 981M | 821M | 475M | 547M | 445M |
| Long-term Investments | 185M | 195M | 164M | 175M | 133M |
| Tax Assets | 0 | 0 | 0 | 436M | 0 |
| Other Non-current Assets | 820M | 686M | 554M | 297M | 1.06B |
| Total Non-current Assets | 6.91B | 6.75B | 6.58B | 7.89B | 8.13B |
| Total Assets | 10.71B | 10.53B | 10.76B | 11.85B | 12.73B |
| Account Payables | 446M | 580M | 418M | 540M | 570M |
| Short-term Debt | 0 | 36M | 0 | 45M | 304M |
| Tax Payables | 0 | 0 | 73M | 0 | 0 |
| Deferred Revenue | 441M | 461M | 505M | 544M | 624M |
| Other Current Liabilities | 493M | 455M | 371M | 326M | 443M |
| Total Current Liabilities | 1.71B | 1.86B | 1.6B | 1.9B | 2.35B |
| Long-term Debt | 2.73B | 2.73B | 2.74B | 3.35B | 3.05B |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 879M | 633M | 580M | 566M | 589M |
| Total Non-current Liabilities | 3.61B | 3.37B | 3.32B | 4.05B | 3.64B |
| Total Liabilities | 5.32B | 5.23B | 4.92B | 5.95B | 5.99B |
| Common Stock | 3M | 3M | 3M | 3M | 3M |
| Retained Earnings | 348M | 324M | 782M | 750M | 1.39B |
| Accumulated OCI | (282M) | (347M) | (327M) | (305M) | (226M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 5.39B | 5.31B | 5.85B | 5.9B | 6.74B |
| Total Debt | 2.73B | 2.77B | 2.74B | 3.57B | 3.35B |
| Net Debt | 1.25B | 1.72B | 1.15B | 2.25B | 1.57B |
Agilent Technologies, Inc.
NYSE:A
Intrinsic Alpha fair value
Locked
Current Price
$177.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.